This study investigates the use of an investigational medication for treating immune-related adverse events in patients who have received cancer immunotherapy.
The study evaluates the safety and effectiveness of the investigational medication in managing these adverse events. It focuses on how well the medication can improve and resolve symptoms in affected patients.
- Who can participate: Adults over 18 years of age with suspected IL-17 mediated immune-related adverse events are eligible. Participants should have been treated or intended to be treated with systemic steroids and must not be receiving curative cancer treatment.
- Study details: Participants will receive the investigational medication through injections over 24 weeks. They will attend regular visits to monitor their response and report any changes in symptoms. A placebo may be used for comparison.
- Study timelines and visits: The study will last 36 weeks. The study requires 9 visits.
How understandable was the trial content above?
Hard to understand
Easy to understand